Your browser doesn't support javascript.
loading
Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba, Ko; Okazaki, Narihiro; Kurogi, Ayako; Watanabe, Tsuyoshi; Mori, Ai; Suzuki, Nobuhiko; Adachi, Koichi; Era, Makoto; Yokota, Kazuaki; Inoue, Takuma; Yabe, Yoshihiro; Furukawa, Keizo; Kondo, Choko; Tsuda, Keiichi; Ota, Shingo; Isobe, Yusaku; Miyazaki, Satsuki; Morimoto, Shimpei; Sato, Shuntaro; Nakashima, Sawako; Tashiro, Shigeki; Yonekura, Akihiko; Tomita, Masato; Osaki, Makoto.
Afiliación
  • Chiba K; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan. Electronic address: kohchiba@estate.ocn.ne.jp.
  • Okazaki N; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Kurogi A; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Watanabe T; Watanabe Orthopedic Clinic, Nagasaki University Hospital, Japan.
  • Mori A; Nagasaki Yurino Hospital, Nagasaki University Hospital, Japan.
  • Suzuki N; Nagasaki Yurino Hospital, Nagasaki University Hospital, Japan.
  • Adachi K; Nagasaki Yurino Hospital, Nagasaki University Hospital, Japan.
  • Era M; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Yokota K; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Inoue T; Juko Memorial Nagasaki Hospital, Nagasaki University Hospital, Japan.
  • Yabe Y; Juko Memorial Nagasaki Hospital, Nagasaki University Hospital, Japan.
  • Furukawa K; Furukawa Orthopedic Clinic, Nagasaki University Hospital, Japan.
  • Kondo C; Kondo Orthopedic Clinic, Nagasaki University Hospital, Japan.
  • Tsuda K; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Ota S; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Isobe Y; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Miyazaki S; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Morimoto S; Clinical Research Center, Nagasaki University Hospital, Japan.
  • Sato S; Clinical Research Center, Nagasaki University Hospital, Japan.
  • Nakashima S; Clinical Research Center, Nagasaki University Hospital, Japan.
  • Tashiro S; Clinical Research Center, Nagasaki University Hospital, Japan.
  • Yonekura A; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Tomita M; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
  • Osaki M; Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University Hospital, Japan.
Bone ; 160: 116416, 2022 07.
Article en En | MEDLINE | ID: mdl-35398293
ABSTRACT

PURPOSE:

The effects of daily teriparatide (20 µg) (D-PTH), weekly high-dose teriparatide (56.5 µg) (W-PTH), or bisphosphonates (BPs) on areal bone mineral density (aBMD), bone turnover markers (BTMs), volumetric BMD (vBMD), microarchitecture, and estimated strength were investigated in postmenopausal osteoporosis patients.

METHODS:

The study participants were 131 women with a history of fragility fractures. They were randomized to receive D-PTH, W-PTH, or BPs (alendronate or risedronate) for 18 months. Dual-energy X-ray absorptiometry (DXA), BTMs, and high-resolution peripheral quantitative CT (HR-pQCT) parameters were evaluated at baseline and after 6 and 18 months of treatment. The primary endpoint was the change (%) in cortical thickness (Ct.Th) after 18 months' treatment compared with baseline.

RESULTS:

DXA showed that D-PTH, W-PTH, and BPs increased lumbar spine aBMD (+12.0%, +8.5%, and +6.8%) and total hip aBMD (+3.0%, +2.1%, and +3.0%), but D-PTH and W-PTH decreased 1/3 radius aBMD (-4.1%, -3.0%, -1.4%) after 18 months. On HR-pQCT, D-PTH increased trabecular vBMD (Tb.vBMD) at the distal radius and tibia after 18 months (+6.4%, +3.7%) compared with the BPs group, decreased cortical volumetric tissue mineral density (Ct.vTMD) (-1.8%, -0.9%) compared with the other groups, increased Ct.Th (+1.3%, +3.9%), and increased failure load (FL) (+4.7%, +4.4%). W-PTH increased Tb.vBMD (+5.3%, +1.9%), maintained Ct.vTMD (-0.7%, +0.2%) compared with D-PTH, increased Ct.Th (+0.6%, +3.6%), and increased FL (+4.9%, +4.5%). The BPs increased Tb.vBMD only in the radius (+2.0%, +0.2%), maintained Ct.vTMD (-0.6%, +0.3%), increased Ct.Th (+0.5%, +3.4%), and increased FL (+3.9%, +2.8%).

CONCLUSIONS:

D-PTH and W-PTH comparably increased Ct.Th, the primary endpoint. D-PTH had a strong effect on trabecular bone. Although D-PTH decreased Ct.vTMD, it increased Ct.Th and total bone strength. W-PTH had a moderate effect on trabecular bone, maintained Ct.vTMD, and increased Ct.Th and total bone strength to the same extent as D-PTH.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis Posmenopáusica / Teriparatido Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Bone Asunto de la revista: METABOLISMO / ORTOPEDIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoporosis Posmenopáusica / Teriparatido Tipo de estudio: Clinical_trials Límite: Female / Humans Idioma: En Revista: Bone Asunto de la revista: METABOLISMO / ORTOPEDIA Año: 2022 Tipo del documento: Article